Maravai Lifesciences Holdings (MRVI) Revenue (2020 - 2026)

Maravai Lifesciences Holdings' Revenue history runs 7 years deep, the most recent figure standing at $65.8 million for Q1 2026.

• On a quarterly basis, Revenue rose 40.53% year-over-year to $65.8 million in Q1 2026; TTM through Mar 2026 was $204.7 million, a 15.35% decrease from a year earlier, with the FY2025 full-year figure at $185.7 million, down 28.34% from the prior year.
• Revenue rose to $65.8 million in Q1 2026 per MRVI's latest filing, from $49.9 million in the prior quarter.
• Across five years, Revenue topped out at $244.3 million in Q1 2022 and bottomed at $41.6 million in Q3 2025.
• The 5-year median for Revenue is $68.9 million (2023), against an average of $99.0 million.
• Across the five-year window, Revenue soared 64.83% in 2022 and slumped 71.61% in 2023, its largest moves.
• Year by year, Revenue stood at $204.7 million in 2022, then plunged by 63.78% to $74.1 million in 2023, then decreased by 23.72% to $56.6 million in 2024, then retreated by 11.83% to $49.9 million in 2025, then surged by 32.03% to $65.8 million in 2026.
• Per Business Quant, the three latest MRVI Revenue figures stand at $65.8 million (Q1 2026), $49.9 million (Q4 2025), and $41.6 million (Q3 2025).